On September 23, EVEREST MED rose 5.23% in regular trading, trading at 30.08 HKD/share, with turnover of approximately 90.17 million HKD. The rally was driven by multiple converging catalysts centered on the company's core product pipeline and improving fundamentals.
On the news front, the company's core product Weshiping (TARPEYO) saw its application for transferring production from overseas to domestic facilities accepted by China's NMPA and included in the priority review process. Localized manufacturing is expected to reduce supply chain risk and improve cost structure. Additionally, Xinbitu (etripamil nasal spray), the company's first cardiovascular innovative drug, received NMPA approval in early September for treating acute episodes of paroxysmal supraventricular tachycardia in adults, marking a key pipeline milestone.
Meanwhile, Chairman Wu Yifang recently purchased a cumulative 28,000 shares on the open market, signaling management confidence. The company reported H1 revenue of RMB 1.148 billion, up 157% year-over-year, with adjusted profit turning positive — driven primarily by robust sales growth in Nefecon and service income under a commercialization agreement with Haisen Bio, which set a three-year procurement ceiling of up to RMB 3.076 billion through the end of fiscal year 2028.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments